C. Boyden Gray and Adam R. Waldman — who are both investors in Altor — sued Dr. Soon-Shiong, a new appointee to the HHS Health IT Advisory Committee, and other pharma executives June 21 in Delaware’s Court of Chancery. The suit alleges Dr. Soon-Shiong low-balled them by $19 million in the purchase, in part by withholding value information about the company.
The suit claims two Altor drugs, currently in Phase 3 clinical trials, are “expected to lead to relatively swift approval to sell the drugs as treatments for cancer into the anticipated $200 billion annual market for immunotherapy” treatment, according to Law360.
The lawsuit calls the acquisition a “squeeze-out merger” of minority stakeholders, noting the company neither appointed a special committee nor an independent party to evaluate the deal, Law360 reports.
More articles on health IT:
3 reasons why Chattanooga is a healthcare hotspot
Tech leaders head to White House, discuss building economic growth
Omada Health lays off 10% of workforce shortly after raising $50M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
